drugset
drugset / Trial / NCT02090400

Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women

NCT02090400 ↗

Phase 4 Completed 110 enrolled Instituto Palacios Pfizer · collab
RandomizedParallel-groupOpen-label

Summary

The aim of this study is see the changes in bone mineral density after discontinuation or stop the use of bisphosphonates and make the switch to bazedoxifene).

Timeline

Start
2013-05
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified 20 mg Oral
Background Calcium carbonate Other / unclassified 500 mg —
Background Vitamin D Other / unclassified 400 iu —

Indications

postmenopausal osteoporosis